Annals of the Rheumatic Diseases
Papers 10000
1 page of 1,000 pages (10k results)
We read with great interest the paper from Glintborg and coauthors ‘To switch or not to switch’ reporting biosimilar etanercept switching in Denmark.1 In the Danish Biologic (DANBIO) cohort, patient treated with originator etanercept (Enbrel) were informed of a mandatory switch to SB4. However, the 25 mg pen or a powder-based preparation of original etanercept (OE) were still available. At 1 year after this decision, the authors reported that only 79% of patients had switched to SB4 and 21% rema...
3 CitationsSource
#1Arghya Chattopadhyay (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 1
#2Varun Dhir (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 10
Last. Sanjay Jain (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 16
view all 3 authors...
We read with interest the article on ‘Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort’ by Julie Sahuguet et al .1 The results are exciting regarding the significantly lower prevalence of vertebral fracture (VF) among patients with ‘early SpA’ and the crucial aspect of recognising vertebral defects as confounding factors. However, certain aspects of this study require further clarifications. First, the external validity of the data rema...
1 CitationsSource
#1Cleo Rogier (EUR: Erasmus University Rotterdam)H-Index: 1
#2Silvia Hayer (Medical University of Vienna)H-Index: 28
Last. Annette H. M. van der Helm-van Mil (EUR: Erasmus University Rotterdam)H-Index: 46
view all 3 authors...
Rheumatoid arthritis (RA) is typically represented as synovitis and bone erosions of small joints. This classic picture resulted from comparing patients with RA with other rheumatic joint diseases for clinical and radiographic characteristics. Although different classification criteria for RA have been developed over time, this classic picture has not changed since the mid-20th century. During the last decennium, advanced imaging modalities, such as MRI and musculoskeletal ultrasound (US), have ...
#1Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
#2Thomas Dörner (Charité)H-Index: 57
Last. Ferdinand C. Breedveld (LUMC: Leiden University Medical Center)H-Index: 61
view all 5 authors...
In their correspondence, Cantini and Benucci1 voice concern regarding the recommendation of our international multidisciplinary task force on biosimilars that ‘a single switch from a bio-originator to one of its biosimilars is safe and effective.’2 This recommendation was based on consistent evidence from randomised controlled trials comparing biosimilars to their respective reference products in patients with rheumatologic diseases, in which subjects treated with a reference product were subseq...
2 CitationsSource
#1Alojzija Hočevar (University of Ljubljana)H-Index: 11
#2Matija Tomšič (University of Ljubljana)H-Index: 28
Last. Ž. RotarH-Index: 5
view all 3 authors...
We read with great interest the article on cardiovascular, thromboembolic and renal outcomes in patients with immunoglobulin A vasculitis (IgAV), published recently online in A nnals of the R heumatic D iseases .1 Tracy et al , estimated both a childhood and an adult onset of IgAV incidence rates and reported an increased risk of hypertension and chronic kidney disease in patients with IgAV, compared with age-matched and sex-matched controls based on retrospective data over a 12-year period extr...
1 CitationsSource
#1Max YatesH-Index: 8
#2R.A. Welikala (KUL: Kingston University)H-Index: 6
Last. Paul J. Foster (UCL Institute of Ophthalmology)H-Index: 64
view all 14 authors...
Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have been associated with an increased future risk of cardiovascular disease (CVD).1 However, it remains uncertain whether this is a consequence of inflammatory disease or relates to a common underlying mechanism. Retinal vascular images are a sensitive measures of vascular health, which are emerging as important biomarkers of future cardiovascular risk with changes affecting arterioles and venules.2 In this study, we assess whethe...
#1Rachel SimpsonH-Index: 1
#2Stephanie Ka Ching Lau (U of O: University of Ottawa)H-Index: 1
Last. Jason Kihyuk LeeH-Index: 1
view all 3 authors...
IgG4-related disease (IgG4-RD) is a rare fibroinflammatory, multisystemic condition with a relapsing-remitting progression.1 The level of serum IgG4 correlates with inflammatory activity and organ involvement.1 Glucocorticoids are first line for IgG4-RD, but there are numerous adverse effects with chronic use.2 Dupilumab is a monoclonal antibody that acts on the interleukin 4 (IL-4) receptor alpha, shared by the IL-4 and IL-13 receptors.1 IL-4 causes isotype switching from IgM to IgG4 and IL-13 ...
7 CitationsSource
#1Elsa Vieira-Sousa (IMM: Instituto de Medicina Molecular)H-Index: 10
#2Pedro AlvesH-Index: 3
Last. R. AguiarH-Index: 1
view all 24 authors...
Objectives To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. Methods Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatology centres. Patients with PsA along with active dactylitis and naive to MTX and biologic disease-modifying antirheumatic drugs (bDMARDs) were randomly assigned to golimumab or placebo, both in combinat...
We thank Dr Wallace et al for their response to our recently published article ‘Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis’, highlighting some methodological limitations of our study.1 2 One of the limitations mentioned by Wallace and colleagues is the inclusion of incident and prevalent cases and since only 15 out of 192 patients were incident cases, generalisability of our ...
1 CitationsSource
#1B. Glintborg (Copenhagen University Hospital)H-Index: 7
#2Anne Loft (AU: Aarhus University)H-Index: 32
Last. Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 24 authors...
Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were receiving originator etanercept and thus were eligible for the switch, as many as four of five (79%) switched to the biosimilar, despite the continued availability of the originator drug (as 25 mg pen or 50 mg powder solution). Among the patients who s...
1 CitationsSource
Top fields of study
Physical therapy
Rheumatoid arthritis
Diabetes mellitus